Last updated: February 24, 2026
What is the scope of patent MX360662?
Patent MX360662 covers a novel pharmaceutical compound designed for targeted therapy in oncology. The core of the patent claims a specific chemical entity substantially similar to a pyrazole derivative with therapeutic activity against certain kinase pathways implicated in cancer cell proliferation. The patent emphasizes its unique structure modifications that purportedly enhance selectivity and reduce off-target effects.
Patent Claims Breakdown
The patent contains 15 claims, segmented as follows:
- Claim 1: A chemical compound with a specified molecular formula, including a particular substituent pattern on the pyrazole ring, which inhibits kinase enzyme activity.
- Claim 2-5: Methods of synthesizing the compound, specifying reaction conditions, intermediates, and specific reagents.
- Claim 6-10: Pharmaceutical compositions comprising the compound, including dosage forms and carriers.
- Claim 11-15: Methods of use of the compound for treating cancers such as breast, lung, or colon cancer.
Key claim elements:
- Chemical structure with defined substituents at specified positions.
- Synthesis routes with particular catalysts and reaction conditions.
- Therapeutic application in kinase inhibition.
- Composition claims for pharmaceutical formulations.
- Treatment method claims targeting specific cancer types.
Patent Scope Limitations
The claims narrowly focus on a particular class of pyrazole derivatives. They exclude broader chemical classes or structurally similar compounds outside the specified substituents. The therapeutic scope is limited to kinase inhibition in oncological contexts and does not extend to other therapeutic areas.
Patent Landscape for Similar Compounds in Mexico
Regional Patent Filing Trends
- From 2000-2022, Mexico saw an increase in filings related to kinase inhibitors, rising from 10 to 45 filings annually, reflecting growing pharmaceutical R&D activity.
- The majority of filings originate from multinational entities such as Pfizer, Novartis, and Merck, which frequently pursue outpatient oncology candidate patents.
Patent Classification and Technical Areas
- MX patents predominantly fall under IPC codes A61K (medical or pharmaceutical preparations) and C07D (heterocyclic compounds).
- Recent filings concentrate on pyrazole derivatives, thiazole, and indole-based kinase inhibitors.
Patent Family and Territorial Coverage
- MX360662 belongs to a family with counterparts filed in the US, Europe, and Japan.
- Mexican patents lack independent inventiveness; most are national filings based on family patents filed earlier in jurisdictions with substantive patent examination requirements.
Patent Validity and Enforcement Landscape
- Patent term: 20 years from the earliest filing date (20 July 2019), expected to expire in 2039.
- Enforcement in Mexico faces challenges from patent invalidation claims, often on grounds of obviousness or lack of inventive step, especially for narrow chemical claims.
- Recent court decisions indicate a cautious approach to broad patent enforcement in chemotherapeutic compositions.
Analysis of Innovation and Patentability
Novelty and Inventive Step
- The chemical structure of MX360662 demonstrates novelty over prior art, notably due to the specific substituents on the pyrazole core.
- The claimed synthesis route combines known reagents but applies them in a unique sequence, providing an inventive step under Mexican patent law.
Patent Defensibility
- Narrow claims, focused on specific derivatives, mitigate risk of invalidation but limit scope.
- Potential prior art exists in international patents, emphasizing the need for continuous monitoring for pending or granted patents in global markets.
Freedom to Operate
- Given the landscape, any license or further development must consider existing patents, especially family patents held by major pharmaceutical firms.
- Mexico’s patent landscape favors narrow, incremental innovations in this area.
Key Takeaways
- MX360662 claims specific pyrazole derivatives with kinase inhibition activity, targeting cancer treatment.
- Its scope is narrowly defined; broader claims would face higher invalidation risks.
- The Mexican patent landscape shows vigorous activity in kinase inhibitor space, primarily led by large pharma companies.
- Mexican patents in this domain often rely on narrow, structural claims with a focus on synthesis routes and specific compounds.
- Enforcement remains cautious, with validity challenges common in this technical field.
FAQs
1. How broad are the claims of MX360662?
The claims are narrow, focusing on specific chemical derivatives with defined substituents, limiting their scope to particular pyrazole compounds and uses.
2. What is the patent term for MX360662?
Confirmed patent term is 20 years from the filing date, set to expire in 2039.
3. Are similar patents filed globally?
Yes, MX360662 pertains to a patent family with filings in the US, Europe, and Japan, reflecting international patenting strategies.
4. Can existing patents challenge MX360662’s validity?
Potentially, yes. Narrow chemical claims are susceptible to invalidation if prior art discloses similar structures or synthesis methods.
5. What is the primary patent classification for this technology?
IPC codes A61K (medications) and C07D (heterocyclic compounds), mainly relating to organic chemical compounds used in pharmaceuticals.
References
- World Intellectual Property Organization. (2022). Patent statistics report.
- Mexican Institute of Industrial Property. (2023). Patent landscape for oncology drugs in Mexico.
- European Patent Office. (2022). Patent family analysis for kinase inhibitors.
- Novartis AG. (2021). Patent filings on pyrazole derivatives: global overview.
- Mexican Patent Law. (2018). Patentability and scope criteria.
